Welcome to our dedicated page for Beigene SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Beigene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Beigene's regulatory disclosures and financial reporting.
BeOne Medicines Ltd. has released its 2026 proxy statement for the June 11, 2026 annual general meeting in Zurich, outlining 20 governance, compensation and capital-authorization proposals. Management highlights 2025 as a transformational year, with the company achieving GAAP profitability for the first time and generating meaningful cash flow.
The letter to shareholders emphasizes BeOne’s growing oncology franchise, led by BTK inhibitor BRUKINSA, which delivered $3.9 billion in 2025 global revenue, up 49% year over year. The company reports more than two million patients treated with its medicines and a workforce of nearly 12,000 employees across six continents.
Shareholders are asked to approve Swiss statutory financial statements, carry forward a Swiss standalone accumulated loss of $7.64 million, discharge directors and executives from liability under Swiss law, elect or re-elect ten directors, and ratify Ernst & Young entities as auditors. Additional resolutions seek say-on-pay approvals, updated equity plans, a mandate to issue up to 20% of issued shares, a 10% share repurchase mandate, and an authorization to allocate shares to Amgen to maintain its ownership percentage in future offerings.
BeOne Medicines Ltd. has released its 2026 proxy statement for the June 11, 2026 annual general meeting in Zurich, outlining 20 governance, compensation and capital-authorization proposals. Management highlights 2025 as a transformational year, with the company achieving GAAP profitability for the first time and generating meaningful cash flow.
The letter to shareholders emphasizes BeOne’s growing oncology franchise, led by BTK inhibitor BRUKINSA, which delivered $3.9 billion in 2025 global revenue, up 49% year over year. The company reports more than two million patients treated with its medicines and a workforce of nearly 12,000 employees across six continents.
Shareholders are asked to approve Swiss statutory financial statements, carry forward a Swiss standalone accumulated loss of $7.64 million, discharge directors and executives from liability under Swiss law, elect or re-elect ten directors, and ratify Ernst & Young entities as auditors. Additional resolutions seek say-on-pay approvals, updated equity plans, a mandate to issue up to 20% of issued shares, a 10% share repurchase mandate, and an authorization to allocate shares to Amgen to maintain its ownership percentage in future offerings.
Baker Bros. Advisors and affiliates report an 8.0% beneficial ownership stake in BeOne Medicines Ltd. (formerly BeiGene Ltd.) through ordinary shares and American Depositary Shares. The main adviser entities each report 115,462,653 Ordinary Shares, while Julian and Felix Baker each report 115,918,313 Ordinary Shares.
The filing notes BeOne’s redomiciliation to Switzerland and name change, and confirms that each ADS represents thirteen Ordinary Shares. It also discloses that Felix J. Baker has been nominated to serve as a director and Lead Director, while two existing Baker-affiliated directors are not standing for re-election. The Baker-managed funds state they hold their position for investment purposes but may increase or decrease holdings over time.
Baker Bros. Advisors and affiliates report an 8.0% beneficial ownership stake in BeOne Medicines Ltd. (formerly BeiGene Ltd.) through ordinary shares and American Depositary Shares. The main adviser entities each report 115,462,653 Ordinary Shares, while Julian and Felix Baker each report 115,918,313 Ordinary Shares.
The filing notes BeOne’s redomiciliation to Switzerland and name change, and confirms that each ADS represents thirteen Ordinary Shares. It also discloses that Felix J. Baker has been nominated to serve as a director and Lead Director, while two existing Baker-affiliated directors are not standing for re-election. The Baker-managed funds state they hold their position for investment purposes but may increase or decrease holdings over time.
BeOne Medicines Ltd. files a preliminary proxy statement for its 2026 Annual General Meeting and asks shareholders to vote on 20 proposals, including approval of its audited Swiss statutory standalone and consolidated financial statements and elections to the Board. The letter highlights that BeOne achieved GAAP profitability in 2025 and reported $3.9 billion in global BRUKINSA revenues, a 49% increase versus the prior year. The company states more than 2 million patients have been treated with its medicines, a workforce of approximately 12,000, and a pipeline with late-stage programs (sonrotoclax, BGB-16673) and anticipated regulatory milestones in H1 2026 and 2027.
BeOne Medicines Ltd. furnished additional 2025 financial details tied to its STAR Market annual report, reconciling PRC GAAP disclosures to U.S. GAAP. Revenue for the year ended December 31, 2025 was $5,343,033 thousand, up from $3,810,241 thousand in 2024, with China contributing $1,679,531 thousand and ex-China $3,663,502 thousand.
The gross profit margin ratio was 66.6% in China and 97.0% ex-China for 2025. Total research and development expenses reached $2,145,868 thousand in 2025 versus $1,953,295 thousand in 2024, driven by key programs such as BRUKINSA, TEVIMBRA, sonrotoclax, BGB-16673 and other projects. The company also reported 6,268,800 vials of key products produced or purchased in 2025, with 5,996,100 vials sold and 2,912,600 vials in stock as of year-end.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised stock options and sold depositary shares in a planned transaction. On April 8, 2026, he exercised options for a total of 4,316 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per share.
These option exercises were represented through 332 American Depositary Shares (ADS), which were then sold at $311.59 per ADS under a pre-arranged Rule 10b5-1 trading plan. Each ADS represents 13 Ordinary Shares. After these transactions and related holdings, he directly holds 318,370 Ordinary Shares, indicating this was a routine liquidity event while maintaining a substantial equity stake.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised stock options and sold depositary shares in a planned transaction. On April 8, 2026, he exercised options for a total of 4,316 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per share.
These option exercises were represented through 332 American Depositary Shares (ADS), which were then sold at $311.59 per ADS under a pre-arranged Rule 10b5-1 trading plan. Each ADS represents 13 Ordinary Shares. After these transactions and related holdings, he directly holds 318,370 Ordinary Shares, indicating this was a routine liquidity event while maintaining a substantial equity stake.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry reported a series of routine equity transactions. He exercised options to acquire 4,433 Ordinary Shares at exercise prices of 14.96, 16.41, and 12.23 per share, which converted into 341 American Depositary Shares (ADSs). Each ADS represents 13 Ordinary Shares. He then sold 341 ADSs at 300.00 per ADS in an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 318,370 Ordinary Shares, indicating he retains a substantial equity position in the company.
OYLER JOHN reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that Chief Executive Officer John Oyler received two equity awards of Ordinary Shares as compensation. On March 6, 2026, he was granted 326,976 shares underlying earned performance share units that vest in 2027, and an additional 117,936 shares underlying earned performance share units that vest in 2028, in each case at no cash cost to him and subject to his continued service, with potential accelerated vesting upon a change of control or certain termination events. Following these awards, Oyler directly holds 5,609,275 Ordinary Shares. The filing also notes several indirect holdings in trusts and an LLC where he disclaims beneficial ownership, plus shares held for his benefit in a Roth IRA account.
OYLER JOHN reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that Chief Executive Officer John Oyler received two equity awards of Ordinary Shares as compensation. On March 6, 2026, he was granted 326,976 shares underlying earned performance share units that vest in 2027, and an additional 117,936 shares underlying earned performance share units that vest in 2028, in each case at no cash cost to him and subject to his continued service, with potential accelerated vesting upon a change of control or certain termination events. Following these awards, Oyler directly holds 5,609,275 Ordinary Shares. The filing also notes several indirect holdings in trusts and an LLC where he disclaims beneficial ownership, plus shares held for his benefit in a Roth IRA account.
Lee Chan Henry reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that SVP and General Counsel Lee Chan Henry received two equity compensation awards on ordinary shares. These awards cover 65,390 and 29,874 shares underlying earned performance share units that vest in 2027 and 2028, subject to continued service. Following these grants, Henry directly holds 318,370 ordinary shares.
Lee Chan Henry reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that SVP and General Counsel Lee Chan Henry received two equity compensation awards on ordinary shares. These awards cover 65,390 and 29,874 shares underlying earned performance share units that vest in 2027 and 2028, subject to continued service. Following these grants, Henry directly holds 318,370 ordinary shares.
BeOne Medicines Ltd. reported that President and Global Head of R&D Wang Lai received equity compensation in the form of performance share units on ordinary shares. The grants cover 112,606 shares vesting in 2027 and 55,029 shares vesting in 2028, subject to continued service and possible accelerated vesting upon certain termination events. After these awards, Wang directly holds 1,619,059 ordinary shares.
He also has indirect exposure to 601,965 ordinary shares held by Wang Holdings LLC, for which he disclaims beneficial ownership, and an indirect economic interest in RMB Shares acquired through an employee participation plan, over which he has no voting or dispositive power.
BeOne Medicines Ltd. reported that President and Global Head of R&D Wang Lai received equity compensation in the form of performance share units on ordinary shares. The grants cover 112,606 shares vesting in 2027 and 55,029 shares vesting in 2028, subject to continued service and possible accelerated vesting upon certain termination events. After these awards, Wang directly holds 1,619,059 ordinary shares.
He also has indirect exposure to 601,965 ordinary shares held by Wang Holdings LLC, for which he disclaims beneficial ownership, and an indirect economic interest in RMB Shares acquired through an employee participation plan, over which he has no voting or dispositive power.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported equity awards and updated share holdings. He received two grants classified as acquisitions of ordinary shares, covering 168,922 and 78,624 shares tied to performance share units. These earned units will vest in 2027 and 2028 if he continues serving the company, with unvested amounts eligible for accelerated vesting upon certain termination events. Following these awards, he directly holds 1,216,524 ordinary shares, 12,365 American Depositary Shares (ADSs) directly, and 4,000 ADSs indirectly through his wife. Each ADS represents 13 ordinary shares.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported equity awards and updated share holdings. He received two grants classified as acquisitions of ordinary shares, covering 168,922 and 78,624 shares tied to performance share units. These earned units will vest in 2027 and 2028 if he continues serving the company, with unvested amounts eligible for accelerated vesting upon certain termination events. Following these awards, he directly holds 1,216,524 ordinary shares, 12,365 American Depositary Shares (ADSs) directly, and 4,000 ADSs indirectly through his wife. Each ADS represents 13 ordinary shares.